Ganetespib (STA-9090)

Catalog No.S1159

For research use only.

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Selleck's Ganetespib (STA-9090) has been cited by 45 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Other HSP (HSP90) Products

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1975 NV73fnIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp MYHJR|UxRThibl2= NFTLXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG0OFY3PSd-MkKxOFQ3PjV:L3G+
NCI-H1975 M13uVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEToe3Q1QCCq NX;UbWF5UUN3ME2xOkBvVQ>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF2NE[2OUc,OjJzNES2OlU9N2F-
Calu-6 NWq1VnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XHXmlEPTB;NkSgcm0> M2n6clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
Calu-1 M12w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTV6IH7N NHfxO4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H2122 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GyXWlEPTB;NUOgcm0> MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
A549 M3;hSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjh[GJiUUN3ME20N{BvVQ>? MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H358 M1LOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ7IH7N Mkf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H1734 M1;4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnaWolrUUN3ME2yPEBvVQ>? Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H727 NGDU[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XaeGlEPTB;Mkigcm0> Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
COR-L23 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPVU21KSzVyPUKyJI5O NF\xTYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1792 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;jfVVLUUN3ME2yNEBvVQ>? M3fGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2009 NHrqfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF7IH7N NWHWZmJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
SK-LU-1 M{frXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF6IH7N MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H2212 M2HJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3KTWM2OD1zNzDuUS=> NF;YepY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H441 NUT5[ldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLtTWM2OD1zNDDuUS=> NX7wcJJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2030 NX3pTlM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNUo96UUN3ME2xNkBvVQ>? NIXXeIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H23 NFz5W5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFzIH7N MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
HOP-62 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjve21KSzVyPUGxJI5O MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
IA-LM M2jBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e4[WlEPTB;MUCgcm0> MkjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H460 NWjMO5c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlniTWM2OD16IH7N NFHMeos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H157 NEXuenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f5VGlEPTB;NzDuUS=> NIrJSJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1355 NFHqUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vGUWlEPTB;NTDuUS=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
VCaP M4LQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6emlEPTB;NzDuUS=> Mn:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUKwNFQoRjJ|MUWyNFA1RC:jPh?=
LNCaP MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnlNIhKSzVyPUigcm0> NGXM[I09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G1NlAxPCd-MkOxOVIxODR:L3G+
Ramos-RA1 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvnTWM2OD15LkSgcm0> NFfFNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
Karpas-299 NUK4Z25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLyfIlKSzVyPUmuOkBvVQ>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
Kasumi-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L0dmlEPTB;NT64JI5O NWjlfo1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
CCRF-CEM (2) M3rkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HxTWlEPTB;Nz6yJI5O NHHafHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
CCRF-CEM (1) M1znXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nqNWlEPTB;MUKuOUBvVQ>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
MOLT-4 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[zUIN5UUN3ME2xNE43KG6P NV;VPXlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
RS4;11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjuWYk4UUN3ME2xN{42KG6P NH;XbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
COG-LL-317 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L5[mlEPTB;ND60JI5O MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
NALM-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYc|VyUUN3ME2xNU44KG6P NULsXGIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
CHLA-136 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP4TWM2OD1{Mz6yJI5O MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-90 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDHTWM2OD1{Mj6zJI5O Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
NB-EBc1 NXTVXYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3POWVKSzVyPUG2Mlghdk1? NXHWbXhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
NB-1643 NY\wXHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\ad2lEPTB;Nz60JI5O M1;JWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
SJ-GBM2 M{TXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7EPXFKSzVyPUGyMlkhdk1? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
CHLA-258 NF:wO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwNDDuUS=> NEjZV3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
CHLA-10 NXvTV4lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5bGlEPTB;NT63JI5O MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
CHLA-9 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMdmlEPTB;ND62JI5O NUP0N49SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
TC-71 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwNTDuUS=> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
CHLA-266 NEHjWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ5LkGgcm0> M1nz[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
BT-12 NX;nd4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml72TWM2OD1zND6zJI5O MnS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
Rh30 NHTGZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme1TWM2OD13Lk[gcm0> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
Rh18 NYjPfFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD14LkKgcm0> M3TKe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
Rh41 NI\RUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPYZXJtUUN3ME2xNE41KG6P Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
RD NHzGU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThibl2= NF;LV|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
K033 MVvBdI9xfG:|aYOgRZN{[Xl? MU[xNFAhdk1? MY[3NkBp Mmntd4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
M23 MkHyRZBweHSxc3nzJGF{e2G7 M4HxXFExOCCwTR?= NVHNdodSPzJiaB?= NWLlO2x{e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= M2TGUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K029 NFLBRnhCeG:ydH;zbZMhSXO|YYm= M3PGOlExOCCwTR?= MnjKO|IhcA>? MUDzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K028 M2XYTGFxd3C2b4Ppd{BCe3OjeR?= NFXYZpoyODBibl2= NYXF[nE4PzJiaB?= MmTud4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K008 MUfBdI9xfG:|aYOgRZN{[Xl? MVqxNFAhdk1? NV[2TmlvPzJiaB?= NH;NdI5{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K033 MWXGeY5kfGmxbjDBd5NigQ>? M2\nVVI2OCCwTR?= MXeyOEBp NUK1OFRDcW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
M23 M1;hdGZ2dmO2aX;uJGF{e2G7 M4j4RlI2OCCwTR?= MnzRNlQhcA>? MmTjbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= NICzNIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K029 M{i0UGZ2dmO2aX;uJGF{e2G7 M3PJb|I2OCCwTR?= NHH1XWEzPCCq NX\lfnF{cW6mdXPld{BIOSCjcoLld5Q> MnXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K028 M3nPZWZ2dmO2aX;uJGF{e2G7 MW[yOVAhdk1? NEfGWZozPCCq NWGwOYhocW6mdXPld{BIOiCjcoLld5Q> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K008 M3Pzd2Z2dmO2aX;uJGF{e2G7 NWTUW|h1OjVyIH7N NYr6[5hJOjRiaB?= MmXlbY5lfWOnczDHNkBienKnc4S= NISxZ2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K033 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M13NOGlEPTB;N{WuOUBvVQ>? NF3PR4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
M23 NV;1SndzS2WubDDWbYFjcWyrdImgRZN{[Xl? MWLJR|UxRTN5LkWgcm0> Mm\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K029 M3H0cWNmdGxiVnnhZoltcXS7IFHzd4F6 NGXhNopKSzVyPUS2JI5O MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K028 M32xR2NmdGxiVnnhZoltcXS7IFHzd4F6 NYWzbpk2UUN3ME24OEBvVQ>? NEjJXlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K008 MnjTR4VtdCCYaXHibYxqfHliQYPzZZk> MljhTWM2OD14MDDuUS=> M1PVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
H3122 M2L3UWNmdGxiVnnhZoltcXS7IFHzd4F6 M1u1clAuOTByMDDuUS=> NULsOGJMPzJiaB?= MVHJR|UxRTFyIH7N Mm\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{OyOlUoRjJ|NUOzNlY2RC:jPh?=
H2228 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFG1V5oxNTFyMECgcm0> NIfubpc4OiCq MlX0TWM2OD1zMzDuUS=> NXzpR|U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N|MzPjVpPkKzOVM{OjZ3PD;hQi=>
A1847 M3jhPGFxd3C2b4Ppd{BCe3OjeR?= NWKxNXR6OTBvMUCwJI5O NWHF[I9qOjRxNEivO|IhcA>? NF:3R3JqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 NIW2TYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-8 MYXBdI9xfG:|aYOgRZN{[Xl? MojQNVAuOTByIH7N M3vEW|I1NzR6L{eyJIg> MW\pcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7 MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN|Y9N2F-
OVCAR-5 MojDRZBweHSxc3nzJGF{e2G7 MUmxNE0yODBibl2= NXmxNHU6OjRxNEivO|IhcA>? M4P1TYlv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm= M3TwflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
SKOV-3 M{LkOmNmdGxiVnnhZoltcXS7IFHzd4F6 NHzVTYwxNTFyMECgcm0> Mlv3O|IhcA>? MnP5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NH;uNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
A1847 NHW0c3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4fPclAuOTByMDDuUS=> NW\XSYx5PzJiaB?= M4jxXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFS3e5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-8 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmD3NE0yODByIH7N NH3kRoc4OiCq MkDYbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NFTqNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFE{Pid-MkO5NFAyOzZ:L3G+
OVCAR-5 NX[3XphQS2WubDDWbYFjcWyrdImgRZN{[Xl? MXiwMVExODBibl2= MoLuO|IhcA>? NX7PT|VmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN|YoRjJ|OUCwNVM3RC:jPh?=
H146  MkDhSpVv[3Srb36gRZN{[Xl? M2C4fFMxKG6P Mor5O|IhcA>? Ml7HbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 M3XKd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
GLC4 NWm3TIwxTnWwY4Tpc44hSXO|YYm= MUCzNEBvVQ>? MVe3NkBp M3jC[Ilv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> MmT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82 MkPhSpVv[3Srb36gRZN{[Xl? NVfSNJR6OzBibl2= M2ewSFczKGh? NFO2RohqdmS3Y3XzJJBmenOrc4TlcpQhTzJxTTDwbIF{\SCjcoLld5Q> NVPyOFJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
AC3 NHX6SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm1UHlkUUN3ME2yOU46KG6P Mkj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H1173 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQOG4xUUN3ME2xNk43OiCwTR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H792 NXXwWWVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS1TlFrUUN3ME20OU4xPyCwTR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H620 M1\vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLPflAxUUN3ME2zNk43PyCwTR?= NIruR5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
N592 NWC5NFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfMPJlKSzVyPUG0MlEzKG6P MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H526 M1LJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;TcWlEPTB;MkGuOlQhdk1? NGL5N209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
H187 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ2Lkm5JI5O Mof5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H146 NWnUOGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrhTWM2OD1{OD61NUBvVQ>? M4jsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H128 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDxOI5KSzVyPU[5MlU2KG6P M3m1N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
H69 M3jKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjXTWM2OD16Mz6zOkBvVQ>? NWS1WWs1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
GLC4 NHTaSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;TTWM2OD1{MD60O{BvVQ>? MkPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82 M33uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFbmlEPTB;M{CuNlchdk1? M3y2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
MDA-MB-231 MXLGeY5kfGmxbjDBd5NigQ>? Ml3LNVAxKG6P MX2yOEBp M2PjNIlvcGmkaYTzJJRp\SCvaXfyZZRwenliYX7kJIlvfmG|aY\lJINieGGlaYT5xsA> M2fkS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezOVQyLz5{NEG3N|U1OTxxYU6=
BT-20  NHvMUFhHfW6ldHnvckBCe3OjeR?= M{nLV|ExOC9{NUCgcm0> M370WFI1KGh? NYjvWJV5emW|dXz0[YQhcW5iYTDkc5NmNWSncHXu[IVvfCCmZYP0ZYJqdGm8YYTpc44hd2ZiRVfGVkwhUUeILVnSMEBOTVRuIHHu[EBEWkGI M33C[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezOVQyLz5{NEG3N|U1OTxxYU6=
MDA-MB-435 MonpSpVv[3Srb36gRZN{[Xl? MUmxNFAhdk1? MkfYN|AhdWmw Mm\BbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y|rF? MoC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
MDA-MB-231 MoXuSpVv[3Srb36gRZN{[Xl? MWWxNFAhdk1? M3KyPVMxKG2rbh?= M3fER4lvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7z NHG0NJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0PFI3PSd-MkSyOFgzPjV:L3G+
HCC2998 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF{ODDuUS=> M4XKcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
SK-CO-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjsTWM2OD16MTDuUS=> M{G1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
LS-123 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vlSWlEPTB;N{Ogcm0> NILhNYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
SNU-C2B NInlcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fBdWlEPTB;NEWgcm0> NIntc4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LS-1034 NITlTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS0UWRKSzVyPUOxJI5O NEO1SVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LoVo M4G5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLITWM2OD1{MjDuUS=> NYi3bVRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
COLO-678 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLvbo15UUN3ME2yNUBvVQ>? NWTWUYdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
NCI-H747 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vFW2lEPTB;MUegcm0> M3u0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
COLO-205 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33wOGlEPTB;MUSgcm0> M1TT[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT 116 M2LyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2IH7N MkCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
HuTu-80 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7zUlk1UUN3ME2xN{BvVQ>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
HCT-15 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRThibl2= M{LYSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
SW620 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTmeZhLUUN3ME24JI5O NXrybmVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
LS-411 N Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVibl2= NELleo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
RKO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HyfmlEPTB;NDDuUS=> MoHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
SW780 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\GeoJKSzVyPUO0OVEhdk1? MmnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
RT4 M1jINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\rTWM2OD1zN{OzJI5O NVXLUJJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
TCCSUP NGrBR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF2MjDuUS=> NET5c5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
MGH-U3 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfrRXFKSzVyPUWzJI5O MnXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
HT-1197 NVPtbHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\1c|M2UUN3ME21N{BvVQ>? MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
5637 M3X0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7kXIR[UUN3ME20OEBvVQ>? Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
35612 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nre2lEPTB;M{igcm0> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
KU-19-19 M{fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfrdmFTUUN3ME2zOkBvVQ>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
LB831-BLC NHLZZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfWTWM2OD1|NDDuUS=> NX\1O5dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
UM-UC3 NXvGR41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzmTWM2OD1|MzDuUS=> MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
647-V NF3oN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLVTWM2OD1{NzDuUS=> MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
HT-1376 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7xdlJKSzVyPUKxJI5O MmflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
J82 NFmzVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEficGZKSzVyPUG4JI5O NXvJNVdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
BFTC NIPrVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF5IH7N NVjPcWF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
SCaBER NUfvcnhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LhVWlEPTB;MUCgcm0> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
639-V MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFyIH7N MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
RT112 NHrMb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvNTXRFUUN3ME25JI5O NIqyR|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
T24 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzIOGtqUUN3ME23JI5O NILtO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SW-1710 M2fC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDBd2dSUUN3ME22JI5O NFrhN3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
DSH1 NUL0VYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\hO2lEPTB;NjDuUS=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
CAL27 M2DVdWN6fG:6aXPpeJkhSXO|YYm= MVSxNE82OCCwTR?= MVyyOEBp NEHuNFZl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NXnyOpdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFU1OzBpPkK1NlA2PDNyPD;hQi=>
Detroit562 MUnDfZRwgGmlaYT5JGF{e2G7 NUjrZ5dkOTBxNUCgcm0> NGrkXpAzPCCq NUH2ZnF1\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyNUSzNEc,OjV{MEW0N|A9N2F-
FUDA MnntR5l1d3irY3n0fUBCe3OjeR?= MUexNE82OCCwTR?= MVSyOEBp NVLX[3FI\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEW0N|AoRjJ3MkC1OFMxRC:jPh?=
SCC25 MmDPR5l1d3irY3n0fUBCe3OjeR?= M{HlSlExNzVyIH7N M4j1cVI1KGh? MoHE[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 MnjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEW0N|AoRjJ3MkC1OFMxRC:jPh?=
HT-29 MmLkSpVv[3Srb36gRZN{[Xl? MnH2OVBvVQ>? NX7PUoZ4OjRiaB?= MXPEUXNQ MVvpcoR2[2WmIFewM2cyKGG{cnXzeC=> MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVQoRjJ3MkGwO|k1RC:jPh?=
HCT-116 M2HFWWZ2dmO2aX;uJGF{e2G7 M4HTOVUxdk1? NX[0VpJXOjRiaB?= MlTvSG1UVw>? MlfVbY5lfWOnZDDHNE9IOSCjcoLld5Q> NX7XR5FIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTRpPkK1NlExPzl2PD;hQi=>
MGC-803 MW\GeY5kfGmxbjDBd5NigQ>? M4e2flAvOS1zMECwJI5O NHjlNWozPCCq MlfabY5lfWOnczDHNk9OKGOnbHytZ5lkdGViYYLy[ZN1 NV;qV4l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
MKN-28 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWPtOGNJOC5zLUGwNFAhdk1? NX;ISFJJPzJiaB?= MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NV;SSXg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
SGC-7901 NHHTXYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIOxRnIxNjFvMUCwNEBvVQ>? Mn7rO|IhcA>? MULpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVfW[WtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
MGC-803 NU\SXlRFS2WubDDWbYFjcWyrdImgRZN{[Xl? M3THelAvOS1zMECwJI5O MV:3NkBp NHP0[mZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYTDVmRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVA5ODVpPkK1OVkxQDB3PD;hQi=>
MV411 MXzBdI9xfG:|aYOgRZN{[Xl? MWGzNE85OC9zNUCvNlUxKG6P NILDOFEzPC92OD:3NkBp NHzzVGZqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM> NIOyOJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4NlU2OCd-MkW4PFI2PTB:L3G+
HL60 M{DLeGFxd3C2b4Ppd{BCe3OjeR?= NFnG[Wk{OC96MD:xOVAwOjVyIH7N Mnq4NlQwPDhxN{KgbC=> MXTpcoR2[2W|IHTvd4Uh\GWyZX7kZY51KGmwZIXjeIlwdiCxZjDhdI9xfG:|aYO= Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1OVAoRjJ3OEiyOVUxRC:jPh?=
TC32 NV\LPJZueUiWUzDhd5NigQ>? M1G2XpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NHznWGdyUFSVIHHzd4F6 M1zxfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NVXYfGhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 M1j2N5FJXFNiYYPzZZk> MlLFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NFi2bldyUFSVIHHzd4F6 NEDzbmNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M2izXJFJXFNiYYPzZZk> NFvIbHJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NGLGVIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MnHHdWhVWyCjc4PhfS=> Mk\4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= M{DUOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NEHqNlhyUFSVIHHzd4F6 M1Pqc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= M3PpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MUXxTHRUKGG|c3H5 M3jsSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 M2L3XZFJXFNiYYPzZZk> MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MkLLdWhVWyCjc4PhfS=> MoLYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= M4T1VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NXjBUVJveUiWUzDhd5NigQ>? MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NHXERmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 NWS1PGZReUiWUzDhd5NigQ>? MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= M3\hXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NIHOfmNyUFSVIHHzd4F6 M3vSPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= M320SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 MoDsdWhVWyCjc4PhfS=> NWXXdVlSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= M3\rfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Assay
Methods Test Index PMID
Western blot EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK ; p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4 ; Survivin / Bcl-2 / Bcl-xl / Mcl-1 ; B-RAF / C-RAF / N-RAS ; HER2 / p-STAT3 / BIM ; CDK1 / Cyclin D1 / Cyclin B1 / p27 ; c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9 ; ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3 ; Wee1 / p-Wee1 / Chk1 / p-Chk1 23418523 25077897 29717218 27834954
Growth inhibition assay Cell viability 23418523
In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
  • (Only for Reference)
Animal Research:[4]
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 40 mg/mL
(109.76 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.

11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Terminated Drug: Ziv-Aflibercept|Drug: Ganetespib Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 2 2014 Phase 1
NCT02008877 Completed Drug: ganetespib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors (MPNST)|Sarcoma Sarcoma Alliance for Research through Collaboration|Synta Pharmaceuticals Corp.|United States Department of Defense December 2013 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?

Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor